

Pierre Quartier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3242726/publications.pdf>

Version: 2024-02-01

191
papers

15,231
citations

18465

62
h-index

19169

118
g-index

204
all docs

204
docs citations

204
times ranked

13382
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. <i>New England Journal of Medicine</i> , 2009, 360, 2416-2425.	13.9	754
2	Chronic Infantile Neurological Cutaneous and Articular Syndrome Is Caused by Mutations in CIAS1, a Gene Highly Expressed in Polymorphonuclear Cells and Chondrocytes. <i>American Journal of Human Genetics</i> , 2002, 71, 198-203.	2.6	718
3	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2396-2406.	13.9	588
4	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. <i>Lancet, The</i> , 2008, 372, 383-391.	6.3	486
5	A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 747-754.	0.5	462
6	Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. <i>Nature Immunology</i> , 2012, 13, 1178-1186.	7.0	410
7	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
8	Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. <i>Arthritis and Rheumatism</i> , 2003, 48, 1093-1101.	6.7	343
9	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. <i>New England Journal of Medicine</i> , 2018, 378, 1908-1919.	13.9	327
10	Autoimmunity in Wiskott-Aldrich Syndrome: Risk Factors, Clinical Features, and Outcome in a Single-Center Cohort of 55 Patients. <i>Pediatrics</i> , 2003, 111, e622-e627.	1.0	294
11	Detection of interferon alpha protein reveals differential levels and cellular sources in disease. <i>Journal of Experimental Medicine</i> , 2017, 214, 1547-1555.	4.2	288
12	Treatment of childhood autoimmune haemolytic anaemia with rituximab. <i>Lancet, The</i> , 2001, 358, 1511-1513.	6.3	287
13	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. <i>Journal of Pediatrics</i> , 1999, 134, 589-596.	0.9	282
14	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1110-1117.	0.5	251
15	Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. <i>Annals of Intensive Care</i> , 2020, 10, 69.	2.2	247
16	Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 258-267.	6.7	239
17	Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. <i>Clinical Immunology</i> , 2004, 110, 22-29.	1.4	224
18	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1388-1393.e8.	1.5	222

#	ARTICLE	IF	CITATIONS
19	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 799-805.	0.5	215
20	Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1792-1802.	6.7	204
21	Protein kinase D at the Golgi controls NLRP3 inflammasome activation. <i>Journal of Experimental Medicine</i> , 2017, 214, 2671-2693.	4.2	197
22	Mevalonate Kinase Deficiency: A Survey of 50 Patients. <i>Pediatrics</i> , 2011, 128, e152-e159.	1.0	195
23	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 790-797.	0.5	187
24	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213030.	0.5	183
25	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2043-2049.	0.5	180
26	Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 265-271.	1.6	178
27	A Large National Cohort of French Patients With Chronic Recurrent Multifocal Osteitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1128-1137.	2.9	178
28	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. <i>Arthritis and Rheumatology</i> , 2016, 68, 2795-2805.	2.9	168
29	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet</i> , 2016, 387, 671-678.	6.3	168
30	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <i>Arthritis and Rheumatism</i> , 2012, 64, 557-567.	6.7	167
31	RNA recognition by human TLR8 can lead to autoimmune inflammation. <i>Journal of Experimental Medicine</i> , 2013, 210, 2903-2919.	4.2	167
32	Lupus-Prone Mice Have an Abnormal Response to Thioglycolate and an Impaired Clearance of Apoptotic Cells. <i>Journal of Immunology</i> , 2003, 170, 3223-3232.	0.4	165
33	Type I interferon-mediated autoinflammation due to DNase II deficiency. <i>Nature Communications</i> , 2017, 8, 2176.	5.8	164
34	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. <i>Journal of Clinical Immunology</i> , 2017, 37, 123-132.	2.0	163
35	Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. <i>European Journal of Immunology</i> , 2005, 35, 252-260.	1.6	155
36	Analysis of TCR, pT14, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. <i>Blood</i> , 2003, 101, 2693-2703.	0.6	152

#	ARTICLE	IF	CITATIONS
37	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
38	Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2002, 117, 965-972.	1.2	128
39	Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. <i>British Journal of Haematology</i> , 2001, 115, 112-118.	1.2	125
40	Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon- β . <i>Rheumatology</i> , 2015, 54, 1507-1517.	0.9	125
41	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	2.7	120
42	Evaluation of a peer support group therapy for HIV-infected adolescents. <i>Aids</i> , 2005, 19, 1501-1508.	1.0	112
43	Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. <i>Rheumatology</i> , 2012, 51, 1855-1859.	0.9	112
44	Allogeneic Bone Marrow Transplantation in Mevalonic Aciduria. <i>New England Journal of Medicine</i> , 2007, 356, 2700-2703.	13.9	110
45	ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1003-1011.	0.5	110
46	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 686-693.	0.5	109
47	Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment. <i>Clinical Infectious Diseases</i> , 2003, 36, e47-e49.	2.9	106
48	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. <i>Rheumatology</i> , 2018, 57, 1203-1211.	0.9	105
49	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 662-667.	0.5	92
50	Clinical features of childhood granulomatosis with polyangiitis (Wegener's granulomatosis). <i>Pediatric Rheumatology</i> , 2014, 12, 18.	0.9	85
51	Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 706-711.	1.0	85
52	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <i>Arthritis Care and Research</i> , 2010, 62, 1533-1541.	1.5	84
53	The emerging role of interleukin-1 β in autoinflammatory diseases. <i>Arthritis and Rheumatism</i> , 2011, 63, 314-324.	6.7	82
54	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1710-1719.	0.5	79

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry. <i>Journal of Rheumatology</i> , 2011, 38, 1436-1440.	1.0	77
56	Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2567-2573.	1.8	75
57	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. <i>Arthritis Care and Research</i> , 2017, 69, 578-586.	1.5	75
58	Anakinra in children and adults with Stillé's disease. <i>Rheumatology</i> , 2019, 58, vi9-vi22.	0.9	75
59	ENTEROVIRAL MENINGOENCEPHALITIS IN X-LINKED AGAMMAGLOBULINEMIA: INTENSIVE IMMUNOGLOBULIN THERAPY AND SEQUENTIAL VIRAL DETECTION IN CEREBROSPINAL FLUID BY POLYMERASE CHAIN REACTION. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 1106-1108.	1.1	73
60	Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 1542-1551.	1.5	72
61	Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. <i>Current Opinion in Immunology</i> , 2015, 32, 90-105.	2.4	69
62	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 821-830.	0.5	68
63	Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. <i>Epilepsia</i> , 2016, 57, 956-966.	2.6	67
64	Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1076-1084.	1.5	64
65	Mutation in the <i>SLC29A3</i> Gene: A New Cause of a Monogenic, Autoinflammatory Condition. <i>Pediatrics</i> , 2013, 131, e1308-e1313.	1.0	64
66	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. <i>Blood</i> , 2000, 96, 2254-2261.	0.6	63
67	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 141.	1.2	62
68	Molecular Basis of a Selective C1s Deficiency Associated with Early Onset Multiple Autoimmune Diseases. <i>Journal of Immunology</i> , 2001, 166, 7612-7616.	0.4	61
69	LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. <i>Clinical Immunology</i> , 2016, 168, 88-93.	1.4	57
70	Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. <i>Clinical Immunology</i> , 2018, 188, 52-57.	1.4	53
71	JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. <i>Rheumatology</i> , 2021, 60, 5801-5808.	0.9	52
72	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 477-490.	1.4	51

#	ARTICLE	IF	CITATIONS
73	Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. <i>Rheumatology</i> , 2010, 49, 1694-1698.	0.9	49
74	Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 40.	1.0	49
75	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 13.	1.6	49
76	Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. <i>Pediatric Rheumatology</i> , 2018, 16, 21.	0.9	49
77	Brief Report: Childhood-onset Systemic Necrotizing Vasculitides: Long-term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015, 67, 1959-1965.	2.9	47
78	ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. <i>RMD Open</i> , 2016, 2, e000236.	1.8	47
79	Mycophenolate mofetil in juvenile dermatomyositis: a case series. <i>Rheumatology International</i> , 2012, 32, 711-716.	1.5	45
80	Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013, 52, 267-275.	0.9	45
81	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i104-12.	0.4	45
82	Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. <i>Rheumatology</i> , 2018, 57, 873-879.	0.9	44
83	Cataract surgery with primary intraocular lens implantation in children with uveitis: Long-term outcomes. <i>Journal of Cataract and Refractive Surgery</i> , 2011, 37, 1977-1983.	0.7	43
84	Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. <i>RMD Open</i> , 2015, 1, e000036-e000036.	1.8	42
85	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	2.5	42
86	Efficacy and safety of TNF α antagonist therapy in patients with juvenile spondyloarthropathies. <i>Joint Bone Spine</i> , 2009, 76, 24-27.	0.8	41
87	Severe cardiac involvement in children with systemic sclerosis and myositis. <i>Journal of Rheumatology</i> , 2002, 29, 1767-73.	1.0	40
88	Germ-line transcription and methylation status of the TCR-J α locus in its accessible configuration. <i>European Journal of Immunology</i> , 1997, 27, 1619-1625.	1.6	38
89	Disease of the Year: Juvenile Idiopathic Arthritis-associated Uveitis Classification and Diagnostic Approach. <i>Ocular Immunology and Inflammation</i> , 2014, 22, 56-63.	1.0	36
90	Haemopoietic stem-cell transplantation for juvenile chronic arthritis. <i>Lancet</i> , The, 1999, 353, 1885-1886.	6.3	34

#	ARTICLE	IF	CITATIONS
91	Tolerance of efavirenz in children. <i>Aids</i> , 2001, 15, 241-243.	1.0	34
92	Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagementâ€”A new target for lupus treatment. <i>Science Advances</i> , 2019, 5, eaav9019.	4.7	34
93	Ocular threat in juvenile idiopathic arthritis. <i>Joint Bone Spine</i> , 2009, 76, 383-388.	0.8	33
94	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Scoreâ€”Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1966-1975.	2.9	33
95	Primary Cytomegalovirus Infection, Atypical Kawasaki Disease, and Coronary Aneurysms in 2 Infants. <i>Clinical Infectious Diseases</i> , 2005, 41, e53-e56.	2.9	32
96	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	2.5	32
97	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 54.	1.2	32
98	Current treatments for juvenile idiopathic arthritis. <i>Joint Bone Spine</i> , 2010, 77, 511-516.	0.8	31
99	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 668-675.	0.4	31
100	The identification of <i>MAFB</i> mutations in eight patients with multicentric carpoâ€”tarsal osteolysis supports genetic homogeneity but clinical variability. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 3023-3029.	0.7	30
101	Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. <i>RMD Open</i> , 2019, 5, e000933.	1.8	29
102	Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 128-135.	1.0	28
103	Inborn errors of metabolism underlying primary immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2014, 34, 753-771.	2.0	27
104	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.5	27
105	Juvenile Idiopathic Arthritis: Classification, Clinical Presentation and Current Treatments. <i>Hormone Research</i> , 2009, 72, 4-12.	1.8	26
106	The lung is involved in juvenile dermatomyositis. <i>Pediatric Pulmonology</i> , 2013, 48, 1016-1025.	1.0	26
107	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon- β signalling. <i>Rheumatology</i> , 2020, 59, 1927-1937.	0.9	26
108	Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). <i>Trials</i> , 2021, 22, 689.	0.7	26

#	ARTICLE	IF	CITATIONS
109	Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies. <i>Joint Bone Spine</i> , 2016, 83, 69-74.	0.8	25
110	Uveitis Related to Juvenile Idiopathic Arthritis: Familial Cases and Possible Genetic Implication in the Pathogenesis. <i>Ocular Immunology and Inflammation</i> , 2010, 18, 172-177.	1.0	24
111	Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 3027-3036.	2.9	24
112	Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2011, 1, 133-136.	1.2	23
113	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 425-429.	1.0	23
114	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 336-346.	2.9	23
115	Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges. <i>Pediatric Rheumatology</i> , 2018, 16, 5.	0.9	22
116	Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. <i>Joint Bone Spine</i> , 2015, 82, 251-257.	0.8	21
117	Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. <i>Rheumatology</i> , 2016, 55, kev359.	0.9	21
118	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 2147-2158.	2.9	21
119	MRI assessment of tenosynovitis in children with juvenile idiopathic arthritis: inter- and intra-observer variability. <i>Pediatric Radiology</i> , 2013, 43, 796-802.	1.1	20
120	Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis. <i>Joint Bone Spine</i> , 2002, 69, 468-481.	0.8	19
121	Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. <i>Joint Bone Spine</i> , 2005, 72, 392-396.	0.8	19
122	Identification of germline monoallelic mutations in <i>IKZF2</i> in patients with immune dysregulation. <i>Blood Advances</i> , 2022, 6, 2444-2451.	2.5	18
123	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 666-669.	2.0	17
124	Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. <i>Joint Bone Spine</i> , 2016, 83, 369-371.	0.8	17
125	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. <i>Arthritis Care and Research</i> , 2020, 72, 1420-1430.	1.5	17
126	Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 179-186.	1.3	16

#	ARTICLE	IF	CITATIONS
127	Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. <i>Journal of Clinical Immunology</i> , 2021, 41, 603-609.	2.0	16
128	Infantile Onset Panniculitis with Uveitis and Systemic Granulomatosis: A New Clinicopathologic Entity. <i>Journal of Pediatrics</i> , 2007, 151, 707-709.	0.9	15
129	Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: A case report. <i>Arthritis Care and Research</i> , 2010, 62, 1346-1350.	1.5	15
130	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 984-989.	2.5	15
131	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019, 58, 1188-1195.	0.9	15
132	Circulating Interferon α Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 195-197.	2.9	15
133	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. <i>Pediatric Rheumatology</i> , 2020, 18, 19.	0.9	15
134	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. <i>Journal of Rheumatology</i> , 2022, 49, 398-407.	1.0	15
135	Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose Sjögren syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 434-9.	0.4	15
136	Radiological Peripheral Involvement in a Cohort of Patients with Polyarticular Juvenile Idiopathic Arthritis at Adulthood. <i>Journal of Rheumatology</i> , 2013, 40, 520-527.	1.0	14
137	Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 903-911.	1.5	14
138	Juvenile dermatomyositis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 113, 1457-1463.	1.0	13
139	From Diagnosis to Prognosis: Revisiting the Meaning of Muscle <i>ISG15</i> Overexpression in Juvenile Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2021, 73, 1044-1052.	2.9	13
140	Propionibacterium acnes Chest Infections in Patients with Chronic Granulomatous Disease: Case Reports. <i>Clinical Infectious Diseases</i> , 2002, 34, 853-854.	2.9	12
141	Severe Abdominal Manifestations in Juvenile Dermatomyositis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 247-251.	0.9	12
142	Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1853-1857.	0.9	11
143	Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis. <i>BioDrugs</i> , 2000, 14, 159-183.	2.2	10
144	ANCA-Associated Glomerulonephritis in Systemic-Onset Juvenile Idiopathic Arthritis. <i>American Journal of Kidney Diseases</i> , 2012, 59, 439-443.	2.1	10

#	ARTICLE	IF	CITATIONS
145	Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 2934.	1.0	10
146	Hyperphosphatemic Familial Tumoral Calcinosis With <i>Galnt3</i> Mutation: Transient Response to Anti-Interleukin-1 Treatments. <i>JBMR Plus</i> , 2019, 3, e10185.	1.3	9
147	Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 567-574.	1.0	9
148	Foveal Serous Retinal Detachment in Juvenile Idiopathic Arthritis-associated Uveitis. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 386-391.	1.0	8
149	Chronic idiopathic musculoskeletal pain in youth: a qualitative study. <i>Pediatric Rheumatology</i> , 2019, 17, 86.	0.9	8
150	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 920-928.	0.4	8
151	AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. <i>Rheumatology</i> , 2022, 61, 4827-4834.	0.9	8
152	Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). <i>American Journal of Hematology</i> , 2017, 92, E79-E81.	2.0	7
153	Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. <i>Rheumatology</i> , 2017, 56, 1814-1816.	0.9	7
154	Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1014-1018.	1.6	7
155	Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2021, 19, 27.	0.9	7
156	Validation de la version française du Childhood Health Assessment Questionnaire (CHAQ) dans les arthrites juvéniles idiopathiques. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002, 69, 898-914.	0.0	6
157	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. <i>Open Access Rheumatology: Research and Reviews</i> , 2011, 3, 9.	0.8	6
158	Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches. <i>Journal of Clinical Medicine</i> , 2022, 11, 1357.	1.0	6
159	Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4578-4587.	1.8	5
160	Inhibition of IFN- γ secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. <i>Rheumatology</i> , 2020, 59, 1171-1174.	0.9	5
161	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFN γ) Monoclonal Antibody. <i>Blood</i> , 2021, 138, 2058-2058.	0.6	5
162	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S5-S6.	2.9	4

#	ARTICLE	IF	CITATIONS
163	Choice of biologic drug among children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2016, 55, 1534-1535.	0.9	4
164	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2021, 48, 898-906.	1.0	4
165	A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2019, 39, 702-712.	2.0	3
166	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e40-e42.	0.5	3
167	Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis. <i>Lancet Rheumatology</i> , The, 2020, 2, e122-e123.	2.2	3
168	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1073-1081.	1.0	3
169	Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrhumdis-2019-216827.	0.5	3
170	A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. <i>Pediatric Rheumatology</i> , 2021, 19, 168.	0.9	3
171	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 26-34.	0.4	3
172	Immunodeficiency and genetic conditions that cause arthritis in childhood. <i>Current Rheumatology Reports</i> , 2002, 4, 483-493.	2.1	2
173	FRI0549...SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. , 2019, , .		2
174	Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab – a real-world experience. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 744-748.	1.6	2
175	Human Papilloma Virus Vaccination in Patients with Rheumatic Diseases in France: A Study of Vaccination Coverage and Drivers of Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 4137.	1.0	2
176	Actualit�s th�rapeutiques des arthrites juv�niles idiopathiques. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.6	1
177	OP0055...EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
178	Comment on: Monogenic mimics of Beh�set�s disease in the young. <i>Rheumatology</i> , 2020, 59, e109-e111.	0.9	1
179	Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice. <i>Pediatric Rheumatology</i> , 2021, 19, 139.	0.9	1
180	L'am�lioration des param�tres de la croissance staturopond�rale est associ�e � la r�ponse au traitement par le m�thotrexate chez les enfants atteints d'arthrite juv�nile idiopathique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2005, 72, 807-812.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Share " Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	0
182	A152: Safety and Effectiveness of Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 to 4 Years. Arthritis and Rheumatology, 2014, 66, S196-S197.	2.9	0
183	Genetic association with articular damage in patients with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2014, 12, .	0.9	0
184	Étude randomisée en double insu testant l'anticorps anti-TNF alpha adalimumab contre placebo dans l'uvite de l'arthrite juvénile idiopathique (Étude ADJUVITE). Revue Du Rhumatisme (Edition Française), 2016, 83, A115.		0
185	Évolution à long terme des enfants atteints de forme pédiatrique de psoriasis cutané et viscéral. Revue Du Rhumatisme (Edition Française), 2016, 83, 194-200.	0.0	0
186	Impact de l'arthrite juvénile idiopathique sur la qualité de vie pendant la période de transition à l'âge adulte à l'ère des biothérapies. Revue Du Rhumatisme (Edition Française), 2016, 83, 281-286.	0.0	0
187	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	1.5	0
188	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	1.5	0
189	AB1071...ALTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOSTIC AND THERAPEUTIC ISSUES. , 2019, , .		0
190	Pourquoi le clinicien est-il en difficulté devant l'adolescent présentant une douleur musculo-squelettique chronique fonctionnelle ? Une étude qualitative. Perspectives Psy, 2021, 60, 235-242.	0.0	0
191	Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. Rheumatology, 2022, , .	0.9	0